Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.

PFS was tested for superiority of subcutaneous versus intravenous amivantamab, with a median PFS of 6.1 months (95% CI, 4.3 to 8.1) and 4.3 months (95% CI, 4.1 to 5.7), respectively, but did not reach statistical significance (HR for disease progression or death, 0.84; 95% CI, 0.64 to 1.10; P = .20; Fig 2 B).

also in 111,027 other papers